On the upside
Rosetta Genomics (Nasdaq: ROSG) reported that the microRNA characteristics of cancer of unknown primary are the same as metastatic tumors of matched primaries.
NuVasive (Nasdaq: NUVA) reported preliminary 2012 revenue that topped expectations and forecast 2013 revenue ahead of estimates.
On the downside
Apollo Group (Nasdaq: APOL) reported lower first quarter earnings as enrollment declined and the for profit educator forecast 2013 revenue below analyst expectations. Five Star Equities wrote that Cell Therapeutics (Nasdaq: CTIC) was an attractive acquisition target but the stock price fell as investors locked in profits from yesterday's rally.
Crosstex Energy (Nasdaq: XTEX) priced its public offering of 7.5 million common units at the discounted price of $15.15 per unit.
In the broad market, advancing issues outpaced decliners by a margin of 5 to 2 on the NYSE and by more than 2 to 1 on Nasdaq. The broader S&P 500 index rose 6 points to 1463.